Singapore, April 16 -- During Abu Dhabi Global Health Week (ADGHW), the Department of Health - Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, and the Abu Dhabi Investment Office (ADIO) signed a Memorandum of Understanding (MoU) with GSK, global biopharmaceutical leader, to collaborate on a Multi-omics Research Institute in Abu Dhabi.
This transformative collaboration aims to accelerate oncology-focused genomic science and precision medicine, enhancing diversification and global representation in genomic research to improve cancer patient outcomes.
Multi-omics is a research approach that studies different biological molecules, such as genes, RNA, proteins, and metabolites, to understand how they interact in an or...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.